Advertisement
Advertisement

ARDX

ARDX logo

Ardelyx, Inc.

3.78
USD
Sponsored
+0.04
+1.07%
Aug 25, 15:56 UTC -4
Closed
exchange

After-Market

3.81

+0.03
+0.79%

Ardelyx, Inc. Profile

About

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.

Info & Links

CEO

Michael Raab

Headquarters

400 Fifth Avenue, Suite 210
Waltham, MA 02451, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.ardelyx.com

Auditor

Ernst & Young LLP

Share holders

23

Employees

489

Ardelyx, Inc. Statistics

Valuation Measures

Market Capitalization2

983.69M

Enterprise Value

1.14B

Enterprise Value/EBITDA(ttm)

-35.46

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.15

Price to Book(mrq)

6.51

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

94.47%

Operating Margin(ttm)

-12.35%

Profit Margin(ttm)

-13.71%

Return on Equity(ttm)

-36.00%

Return on Invested Capital(ttm)

-15.23%

Return on Assets(ttm)

-10.77%

Income Statement

Revenue(ttm)

450.89M

Revenue Per Share(ttm)

1.81

Gross Profit(ttm)

425.49M

EBITDA(ttm)3

-32.11M

Net Income Available to Common(ttm)

-55.70M

Diluted EPS(ttm)

-0.22

Share Statistics

Beta (5Y Monthly)

0.70

52-Week Change

-38.13%

S&P 500 52-Week Change

19.04%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

249.19M

Dividend Yield

0.00%

Float4

235.98M

% Held by Insiders

5.30%

% Held by Institutions

58.92%

Balance Sheet

Total Cash(mrq)

281.83M

Total Cash Per Share(mrq)

1.13

Total Debt(mrq)

251.82M

Total Debt/Equity(mrq)

168.99%

Current Ratio(mrq)

3.34%

Quick Ratio(mrq)

3.15%

Book Value Per Share(mrq)

0.60

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.16

Free Cash Flow(ytd)

-38.72M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement